作者:Nguyen Minh Phuc、Zhexue Wu、Yuseok O、Jee-Hyun Lee、Sangtaek Oh、Gyu-Yong Song、Kwang-Hyeon Liu
DOI:10.1124/dmd.117.075036
日期:2017.7
a mechanism-based inhibitor. LKY-047 was found to be a selective CYP2J2 inhibitor with no inhibitory effect on other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A (IC50 > 50 μM). These in vitro data support the use of LKY-047 as a selective CYP2J2 inhibitor with potential application in the identification of P450 isoforms responsible for drug metabolism in reaction phenotyping
目前尚无适用于反应表型的高选择性细胞色素P450 CYP2J2(CYP2J2)抑制剂。(7S)-(+)-(4-硝基-苯基)-丙烯酸,8,8-二甲基-2-氧代-6,7-二氢-2H,8H-吡喃[3,2-g] chromen-7合成了一种decursin衍生物-yl-ester(LKY-047),并评估了其对CYP2J2以及人肝微粒体(HLM)中其他细胞色素P450(P450)酶的抑制作用。LKY-047被证明是CYP2J2介导的阿司咪唑O-去甲基化酶和特非那定羟化酶活性的强竞争抑制剂,Ki值分别为0.96和2.61μM。它也作为CYP2J2介导的巴斯马汀羟基化的非竞争性抑制剂,Ki值为3.61μM。将LKY-047与HLM和NADPH一起预孵育不会改变抑制效能,表明它不是基于机制的抑制剂。发现LKY-047是一种选择性CYP2J2抑制剂,对其他人类P450如CYP 1A2、2A6、2B6、2C